Operational sustainability is challenged by a persistent cash burn, with free cash flow margins of -40.5% in 2025Q2 indicating an inability to fund operations internally.
| Cash from Operations | -1.99M | -2.43M | -2.03M | -2.92M | -1.53M | 443.92K | -411.88K |
| Operating CF Margin % | - | -35.58% | -50.73% | -78.72% | -40.56% | 9.74% | -4.64% |
| Operating CF Growth % | 2.18% | -19.26% | 30.27% | -91.11% | -443.94% | 207.78% | - |
| Net Income | 266.67K | -2.77M | -17.6M | -8.44M | -24.95M | 900.4K | 198.97K |
| Depreciation & Amortization | 272.07K | 406.48K | 173.22K | 119.35K | 172.02K | 264.1K | 285.38K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 4.38K | -4.38K | 0 | -48.23K | -27.68K | -32.27K |
| Other Non-Cash Items | -2.03M | 160.35K | 15.21M | 4.87M | 22.18M | -1.87M | -85.21K |
| Working Capital Changes | -504.54K | -230.03K | 194.93K | 531.2K | 1.12M | 1.18M | -778.75K |
| Change in Receivables | -228.79K | -166.99K | 82.35K | -32.97K | -174.82K | -263.95K | 735.82K |
| Change in Inventory | -106.94K | 45.43K | -126.27K | 0 | 3.69M | 0 | 0 |
| Change in Payables | 0 | -12.95K | 15.99K | 1.27K | -1.13M | 1.38M | -791.25K |
| Cash from Investing | -166.97K | -104.45K | -147.77K | 0 | -268.21K | -356.18K | 179.34K |
| Capital Expenditures | -118.83K | -77.26K | -116.03K | -5 | -18.14K | -1.96K | -76.06K |
| CapEx % of Revenue | 2.3% | 1.13% | 2.89% | 0% | 0.48% | 0.04% | 0.86% |
| Acquisitions | 552 | 0 | 16.3K | 0 | -3.4K | -354.23K | 255.41K |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -48.69K | -27.19K | -48.03K | 5 | -246.66K | 0 | 0 |
| Cash from Financing | 1.94M | 2.55M | 2.32M | 2.35M | 2.49M | -168.37K | 212.51K |
| Debt Issued (Net) | 0 | 2.22M | 2.16M | 1.44M | 1.4M | -6.69K | -5.13K |
| Equity Issued (Net) | 0 | 100K | 50K | 790K | 1.1M | 0 | 35.11K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.94M | 234.46K | 115.14K | 121.88K | -9.47K | -161.69K | 182.52K |
| Net Change in Cash | -390.58K | 107.54K | 40.05K | -586.93K | 594.49K | -60.77K | -66.85K |
| Free Cash Flow | -2.11M | -2.53M | -2.15M | -2.92M | -1.54M | 441.96K | -487.94K |
| FCF Margin % | -40.9% | -37.11% | -53.62% | -78.72% | -41.04% | 9.7% | -5.5% |
| FCF Growth % | -29.48% | -17.68% | 26.29% | -88.86% | -449.57% | 190.58% | - |
| FCF per Share | -1.14 | -1.36 | -1.33 | -2.55 | -2.57 | 0.96 | -1.31 |
| FCF Conversion (FCF/Net Income) | -7.91x | 0.88x | 0.13x | 0.29x | 0.06x | 0.51x | -2.35x |
| Interest Paid | 24.26K | 6K | 55.38K | 17.52K | 19.59K | 110.83K | 66.19K |
| Taxes Paid | 0 | 32.16K | 11.63K | 42.9K | 156.34K | 30.18K | 12.58K |
Imminent liquidity and dilution risk
As reported in financial statements, EUDA's operating cash flow consistently trails net income, with the most recent OCF/NI ratio of 1.01 suggesting that reported earnings are not translating into actual liquidity, a trend that warrants significant caution regarding the underlying quality of the company's reported profitability.
The persistent gap between accounting net income and cash generation indicates that the company's earnings are heavily influenced by non-cash items or accruals that do not support operational sustainability. Investors should monitor whether this divergence is a result of aggressive revenue recognition or simply the high cost of maintaining a service-heavy digital health platform.
Based on EUDA's reported figures, the company's free cash flow trajectory is consistently negative, with recent quarterly FCF margins hovering around -40.5%, indicating that the business model is currently unable to self-fund its operations without continuous reliance on external capital injections to cover ongoing cash burn.
The inability to generate positive free cash flow suggests that the company's growth initiatives are currently value-destructive from a cash perspective. This trend implies that until the firm can achieve significant operating leverage, it will remain tethered to the volatility of capital markets for survival.
According to recent SEC filings, EUDA's working capital dynamics show significant quarterly fluctuations, including a negative $160.6K impact in the most recent period, which suggests that the company is struggling to manage its cash conversion cycle effectively amidst its rapid expansion in the Singaporean market.
The erratic nature of working capital changes may indicate difficulties in collecting receivables from corporate partners or managing pharmaceutical inventory levels. Such instability in cash management often precedes liquidity crunches, especially when the company lacks a robust cash buffer to absorb these operational timing differences.
As evidenced by the provided data, the cash flow statement reveals a critical liquidity position of only $345,145, which, when compared to the consistent quarterly cash burn, suggests that the company's current operational structure is unsustainable without immediate and potentially highly dilutive external financing events.
The cash flow statement masks the severity of the company's reliance on external funding by failing to highlight the lack of a sustainable path to positive cash flow. Investors should be wary that the current burn rate may necessitate a down-round or restrictive debt financing, which would fundamentally alter the equity value proposition.
Quick answers to the most common questions about buying EUDA stock.
EUDA Health Holdings Limited (EUDA) generated $-2.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
EUDA Health Holdings Limited (EUDA) reported negative free cash flow of $2.5M in 2025, indicating capital requirements exceeded cash from operations.
EUDA Health Holdings Limited (EUDA) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.